Wikidata

(Q45231524)

English

A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia

scientific article published in March 2005

In more languages

Statements

title
A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
15661261
retrieved
11 December 2017
author name string
Kenneth S Bauer
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
15661261
retrieved
11 December 2017
Judith E Karp
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
15661261
retrieved
11 December 2017
Tushar S Garimella
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
15661261
retrieved
11 December 2017
Suhlan Wu
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed ID
15661261
retrieved
11 December 2017
Ming Tan
series ordinal
5
1 reference
stated in
Europe PubMed Central
PubMed ID
15661261
retrieved
11 December 2017
Douglas D Ross
series ordinal
6
1 reference
stated in
Europe PubMed Central
PubMed ID
15661261
retrieved
11 December 2017
publication date
1 March 2005
1 reference
stated in
Europe PubMed Central
PubMed ID
15661261
retrieved
11 December 2017
page(s)
263-271
1 reference
stated in
Europe PubMed Central
PubMed ID
15661261
retrieved
11 December 2017

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q45231524&oldid=2070742680"